Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...
If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...
Synthego granted global license to manufacture and distribute AZ's CRISPR gene editing enzyme, eSpOT-ON.
Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.
Scribe announced its initial research collaboration with Sanofi for CRISPR-based cell therapies to address oncology ...
ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...
Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...
Caribou has initiated the GALLOP Phase 1 clinical trial, an open-label, multicenter clinical trial designed to evaluate a single infusion of CB-010 in adult patients with LN and ERL. CB-011, a ...
Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...
The revolution in artificial intelligence (AI) and genetic engineering represents an unprecedented turning point in human ...
Intellia Therapeutics (NTLA) stock falls, sending its gene editing rivals lower, as Wall Street reacts to its latest layoff ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback